ClinicalTrials.gg
Not yet recruitingNCT07609654OASIS-AFUpdated Oct 20, 2026

Oral Anticoagulation in Patients With Prior Deep Intracerebral Hemorrhage, Atrial Fibrillation, and Ischemic Stroke

A Phase 4 interventional study of Apixaban and No Oral Anticoagulation Strategy in Intracerebral Hemorrhage, Atrial Fibrillation (AF) and Ischemia Stroke, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Phase 4, Interventional, and Treatment

How we know

Updated Oct 20, 2026First site in ChinaStart date moved+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
852
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 123 studies in Cerebral Hemorrhage with a site in China — 59 open to participants now, 62 under way, 5 of them phase 3. Cerebral Hemorrhage · China.

Planned enrollment
8th of 77
852 · median 180
Started
2026
with 14 others
Phase 4
4 of 123
3 open now
Primary completion
2031-11
later than 59 of 61 live
Registered
114th of 123
by date

Among the 123 studies in Cerebral Hemorrhage with a site in China, this one is the 8th largest by planned enrollment of the 77 interventional ones that give a count, is one of 15 that started in 2026, is one of 4 in phase 4, reaches primary completion later than 59 of the 61 other live ones, and was the 114th registered.

Cerebral Hemorrhage

458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.

Browse Cerebral Hemorrhage studies →

Open to participants now

59 of the 123 studies in Cerebral Hemorrhage with a site in China are open now. Recruiting first, the newest first:

54 more — sign in →

All 59 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 115 Cerebral Hemorrhage studies recruiting now, 61 (53%) set no upper age limit and 9 (8%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 123 studies in Cerebral Hemorrhage with a site in China, or all of them as a file.
02

Study summary

This prospective, multicenter, randomized, open-label, blinded-endpoint trial aims to evaluate the efficacy and safety of oral anticoagulation with apixaban in patients with non-valvular atrial fibrillation, ischemic stroke, and a history of spontaneous, non-traumatic deep intracerebral hemorrhage. Eligible intracerebral hemorrhage is located in the basal ganglia, thalamus, pons, or deep cerebellum and is non-lobar and non-intraventricular. Participants will be randomized in a 1:1 ratio to apixaban or a no-oral-anticoagulation strategy. Participants assigned to apixaban will receive 5 mg twice daily, with dose reduction according to the approved prescribing information when indicated. Participants assigned to no oral anticoagulation may receive single antiplatelet therapy or no antithrombotic therapy at the discretion of the treating physician. Participants will be followed for at least 6 months and up to 36 months. The primary outcome is the first occurrence of recurrent ischemic stroke or recurrent intracerebral hemorrhage, whichever occurs first.

03

Conditions studied

  • Intracerebral Hemorrhage
  • Atrial Fibrillation (AF)
  • Ischemia Stroke

Keywords

  • Deep Intracerebral Hemorrhage
  • Non-lobar Intracerebral Hemorrhage
  • Atrial Fibrillation
  • Ischemic Stroke
  • Apixaban
  • Oral Anticoagulation
04

Who can participate

The criteria were revised on the registry on Oct 20, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years.
  2. Ischemic stroke.
  3. History of spontaneous, non-traumatic deep intracerebral hemorrhage confirmed by CT or MRI, located in the basal ganglia, thalamus, pons, or deep cerebellum, with no lobar cortical involvement and no intraventricular hemorrhage.
  4. Non-valvular atrial fibrillation, including paroxysmal, persistent, or permanent atrial fibrillation.
  5. Written provided by the participant or a legally authorized representative.

Exclusion criteria

Exclusion Criteria:

  1. Modified Rankin Scale (mRS) score >3.
  2. MRI evidence of cortical superficial siderosis (cSS) or severe lobar cerebral microbleeds.
  3. Severe uncontrolled hypertension to medical therapy.
  4. Severe renal impairment with (CrCl) \<30 mL/min.
  5. Requirement for continuous oral anticoagulation for an indication other than atrial fibrillation, such as a mechanical heart valve or venous thromboembolism.
  6. Requirement for continued antiplatelet therapy that cannot be replaced by oral anticoagulation.
  7. to apixaban according to the approved prescribing information, other than the history of spontaneous intracerebral hemorrhage, including , active bleeding, other high-risk bleeding lesions, or hepatic disease associated with coagulopathy and bleeding risk.
  8. Previous or planned left atrial appendage occlusion.
  9. Pregnancy, breastfeeding, or planned pregnancy during the study period.
  10. Inability to comply with study procedures or an expected \<6 months.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
852 participants (estimated)

Study arms

  • Experimental
    Apixaban

    Participants assigned to the anticoagulation group will receive oral apixaban 5 mg twice daily. Dose reduction will be performed according to the approved prescribing information when indicated.

    Drug: Apixaban

  • Active comparator
    Non-Anticoagulation Therapy

    Participants will not receive oral anticoagulation. Single antiplatelet therapy, such as aspirin or clopidogrel, or no antithrombotic therapy is permitted at the discretion of the treating physician according to clinical guidelines and individual patient characteristics.

    Other: No Oral Anticoagulation Strategy

Interventions

  • Oral apixaban 5 mg twice daily, with dose reduction according to the approved prescribing information when indicated.

  • OtherNo Oral Anticoagulation Strategy

    No oral anticoagulation; single antiplatelet therapy or no antithrombotic therapy is permitted at the discretion of the treating physician.

06

What researchers measure

Primary outcomes

  1. Time to First Occurrence of Recurrent Ischemic Stroke or Recurrent Intracerebral Hemorrhage

    Time from randomization to the first occurrence of recurrent ischemic stroke or recurrent intracerebral hemorrhage, whichever occurs first.

    Time frame: From randomization to the first qualifying event or the end of follow-up, up to 36 months

Secondary outcomes

  1. First Recurrent Ischemic Stroke

    Occurrence of the first recurrent ischemic stroke during follow-up.

    Time frame: Up to 36 months

  2. First Recurrent Intracerebral Hemorrhage

    Occurrence of the first recurrent intracerebral hemorrhage during follow-up.

    Time frame: Up to 36 months

  3. Vascular Death

    Death due to a vascular cause during follow-up.

    Time frame: Up to 36 months

  4. All-Cause Death

    Death from any cause during follow-up.

    Time frame: Up to 36 months

  5. Major Bleeding Events

    Major bleeding events defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria.

    Time frame: Up to 36 months

  6. Modified Rankin Scale (mRS) Score Distribution

    Distribution of scores on the modified Rankin Scale, ranging from 0 (no symptoms) to 6 (death), with higher scores indicating greater disability.

    Time frame: 6, 12, 24, and 36 months after randomization

Other outcomes

  1. Clinically Relevant Non-Major Bleeding

    Bleeding that does not meet the ISTH criteria for major bleeding but results in hospitalization, medical intervention, or discontinuation of study treatment.

    Time frame: Up to 36 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Oct 2026; primary completion for Nov 2031, 60 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: start Jun 2026 → Oct 2026, primary completion Jun 2029 → Nov 2031 and completion Sep 2029 → Feb 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
May 27, 2026
StartEst.
Oct 26, 2026was Jun 2026
Primary completionEst.
Nov 1, 2031was Jun 2029
CompletionEst.
Feb 1, 2032was Sep 2029
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in China
Show site
  • Department of Neurology, the Second Affiliated Hospital of Zhejiang University, School of Medicine · Hangzhou, China
Oct 20, 2026
Start date
Jun 1, 2026→Oct 26, 2026
Oct 20, 2026
Primary completion
Jun 1, 2029→Nov 1, 2031
Oct 20, 2026
Study completion
Sep 1, 2029→Feb 1, 2032
Oct 20, 2026
Eligibility
2 inclusion criteria edited, 2 added, 2 removed; 6 exclusion criteria edited, 4 added, 3 removed
What changed in the criteria
Inclusion criteria
  • RemovedDiagnosis of acute ischemic stroke, with no evidence of hemorrhagic transformation confirmed by acute neuroimaging (MRI and CT).
  • RemovedDocumented history of spontaneous intracerebral hemorrhage (ICH).
  • AddedIschemic stroke.
  • AddedHistory of spontaneous, non-traumatic deep intracerebral hemorrhage confirmed by CT or MRI, located in the basal ganglia, thalamus, pons, or deep cerebellum, with no lobar cortical involvement and no intraventricular hemorrhage.
  • EditedConfirmed nonNon-valvular atrial fibrillation (, including paroxysmal, persistent, or permanent subtypes)atrial fibrillation.
  • EditedProvision of writtenWritten informed consent provided by the patientparticipant or a legally authorized representative.
Exclusion criteria
  • EditedSevere baseline disability, defined as a pre-stroke Modified Rankin Scale (mRS) score > 43.
  • RemovedIntracerebral hemorrhage definitively caused by underlying structural vascular lesions (e.g., AVM, aneurysm) or systemic diseases.
  • AddedMRI evidence of cortical superficial siderosis (cSS) or severe lobar cerebral microbleeds.
  • EditedSevere, uncontrolled hypertension refractory to medical therapy.
  • EditedSevere renal impairment, defined as an estimated Creatinine Clearance with creatinine clearance (CrCl) < 30 mL/min.
  • RemovedClinical indications necessitating continuous oral anticoagulation therapy other than atrial fibrillation (e.g., mechanical prosthetic heart valves, deep vein thrombosis, pulmonary embolism).
  • AddedRequirement for continuous oral anticoagulation for an indication other than atrial fibrillation, such as a mechanical heart valve or venous thromboembolism.
  • AddedRequirement for continued antiplatelet therapy that cannot be replaced by oral anticoagulation.
  • EditedDocumented contraindicationsContraindication to direct oral anticoagulantsapixaban according to the product summaryapproved prescribing information, other than the history of characteristics (excluding the previous spontaneous ICH)intracerebral hemorrhage, including but not limited to hypersensitivity, active clinically significant bleeding, other high-risk bleeding lesions, or hepatic disease associated with coagulopathy and clinically relevant bleeding risk.
  • EditedPrior deployment of,Previous or planned procedure for, a left atrial appendage occlusion (LAAO) device.
  • EditedWomen who are pregnantPregnancy, breastfeeding, or planning to become pregnantplanned pregnancy during the trialstudy period.
  • RemovedEstimated life expectancy of less than 1 year due to concomitant terminal illness.
  • AddedInability to comply with study procedures or an expected life expectancy <6 months.
Oct 20, 2026
Interventions
Added Drug: Apixaban·No Oral Anticoagulation Strategy; removed Drug: Direct Oral Anticoagulants (DOACs)·Drug: Antiplatelet Therapy or No Antithrombotic Therapy. Arms added: Apixaban; arms removed: Anticoagulation Therapy
Oct 20, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Incidence of the Composite Endpoint of Recurrent StrokeNow Time to First Occurrence of Recurrent Ischemic Stroke or Recurrent Intracerebral HemorrhageTime frame: Up to 12 months → From randomization to the first qualifying event or the end of follow-up, up to 36 months
Oct 20, 2026
Secondary outcomes
5 edited, 2 added, 3 removed
What changed in the outcomes
  • EditedIncidence ofFirst Recurrent Ischemic StrokeTime frame: Up to 12 months. → Up to 36 months
  • EditedIncidence ofFirst Recurrent Intracerebral Hemorrhage (ICH)Time frame: Up to 12 months. → Up to 36 months
  • EditedIncidence of Vascular DeathTime frame: Up to 12 months → Up to 36 months
  • EditedAll-Cause Mortality RateDeathTime frame: Up to 12 months → Up to 36 months
  • EditedIncidence of Major Bleeding EventsTime frame: Up to 12 months → Up to 36 months
  • AddedModified Rankin Scale (mRS) Score DistributionTime frame: 6, 12, 24, and 36 months after randomization
  • RemovedTime to First Occurrence of Recurrent Ischemic StrokeTime frame: Up to 12 months
  • RemovedTime to First Occurrence of Recurrent Intracerebral Hemorrhage (ICH)Time frame: Up to 12 months
  • RemovedIncidence of Clinically Relevant Non-Major (CRNM) BleedingTime frame: Up to 12 months
  • Addedother outcomeClinically Relevant Non-Major BleedingTime frame: Up to 36 months
Oct 20, 2026
Title
Oral Anticoagulation After Stroke With Prior ICH in Subjects With AF→Oral Anticoagulation in Patients With Prior Deep Intracerebral Hemorrhage, Atrial Fibrillation, and Ischemic Stroke
Oct 20, 2026
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University→Second Affiliated Hospital, Zhejiang University, School of Medicine
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    1 site added — first site in China
    Show site
    • Department of Neurology, the Second Affiliated Hospital of Zhejiang University, School of Medicine · Hangzhou, China
    Start date Jun 1, 2026→Oct 26, 2026
    Primary completion Jun 1, 2029→Nov 1, 2031
    Study completion Sep 1, 2029→Feb 1, 2032
    Eligibility 2 inclusion criteria edited, 2 added, 2 removed; 6 exclusion criteria edited, 4 added, 3 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedDiagnosis of acute ischemic stroke, with no evidence of hemorrhagic transformation confirmed by acute neuroimaging (MRI and CT).
    • RemovedDocumented history of spontaneous intracerebral hemorrhage (ICH).
    • AddedIschemic stroke.
    • AddedHistory of spontaneous, non-traumatic deep intracerebral hemorrhage confirmed by CT or MRI, located in the basal ganglia, thalamus, pons, or deep cerebellum, with no lobar cortical involvement and no intraventricular hemorrhage.
    • EditedConfirmed nonNon-valvular atrial fibrillation (, including paroxysmal, persistent, or permanent subtypes)atrial fibrillation.
    • EditedProvision of writtenWritten informed consent provided by the patientparticipant or a legally authorized representative.
    Exclusion criteria
    • EditedSevere baseline disability, defined as a pre-stroke Modified Rankin Scale (mRS) score > 43.
    • RemovedIntracerebral hemorrhage definitively caused by underlying structural vascular lesions (e.g., AVM, aneurysm) or systemic diseases.
    • AddedMRI evidence of cortical superficial siderosis (cSS) or severe lobar cerebral microbleeds.
    • EditedSevere, uncontrolled hypertension refractory to medical therapy.
    • EditedSevere renal impairment, defined as an estimated Creatinine Clearance with creatinine clearance (CrCl) < 30 mL/min.
    • RemovedClinical indications necessitating continuous oral anticoagulation therapy other than atrial fibrillation (e.g., mechanical prosthetic heart valves, deep vein thrombosis, pulmonary embolism).
    • AddedRequirement for continuous oral anticoagulation for an indication other than atrial fibrillation, such as a mechanical heart valve or venous thromboembolism.
    • AddedRequirement for continued antiplatelet therapy that cannot be replaced by oral anticoagulation.
    • EditedDocumented contraindicationsContraindication to direct oral anticoagulantsapixaban according to the product summaryapproved prescribing information, other than the history of characteristics (excluding the previous spontaneous ICH)intracerebral hemorrhage, including but not limited to hypersensitivity, active clinically significant bleeding, other high-risk bleeding lesions, or hepatic disease associated with coagulopathy and clinically relevant bleeding risk.
    • EditedPrior deployment of,Previous or planned procedure for, a left atrial appendage occlusion (LAAO) device.
    • EditedWomen who are pregnantPregnancy, breastfeeding, or planning to become pregnantplanned pregnancy during the trialstudy period.
    • RemovedEstimated life expectancy of less than 1 year due to concomitant terminal illness.
    • AddedInability to comply with study procedures or an expected life expectancy <6 months.
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Incidence of the Composite Endpoint of Recurrent StrokeNow Time to First Occurrence of Recurrent Ischemic Stroke or Recurrent Intracerebral HemorrhageTime frame: Up to 12 months → From randomization to the first qualifying event or the end of follow-up, up to 36 months
    Secondary outcomes 5 edited, 2 added, 3 removed
    What changed in the outcomes
    • EditedIncidence ofFirst Recurrent Ischemic StrokeTime frame: Up to 12 months. → Up to 36 months
    • EditedIncidence ofFirst Recurrent Intracerebral Hemorrhage (ICH)Time frame: Up to 12 months. → Up to 36 months
    • EditedIncidence of Vascular DeathTime frame: Up to 12 months → Up to 36 months
    • EditedAll-Cause Mortality RateDeathTime frame: Up to 12 months → Up to 36 months
    • EditedIncidence of Major Bleeding EventsTime frame: Up to 12 months → Up to 36 months
    • AddedModified Rankin Scale (mRS) Score DistributionTime frame: 6, 12, 24, and 36 months after randomization
    • RemovedTime to First Occurrence of Recurrent Ischemic StrokeTime frame: Up to 12 months
    • RemovedTime to First Occurrence of Recurrent Intracerebral Hemorrhage (ICH)Time frame: Up to 12 months
    • RemovedIncidence of Clinically Relevant Non-Major (CRNM) BleedingTime frame: Up to 12 months
    • Addedother outcomeClinically Relevant Non-Major BleedingTime frame: Up to 36 months
    Interventions Added Drug: Apixaban·No Oral Anticoagulation Strategy; removed Drug: Direct Oral Anticoagulants (DOACs)·Drug: Antiplatelet Therapy or No Antithrombotic Therapy. Arms added: Apixaban; arms removed: Anticoagulation Therapy
    Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University→Second Affiliated Hospital, Zhejiang University, School of Medicine
    Title Oral Anticoagulation After Stroke With Prior ICH in Subjects With AF→Oral Anticoagulation in Patients With Prior Deep Intracerebral Hemorrhage, Atrial Fibrillation, and Ischemic Stroke
    + 5 other changes: index terms, verification date, description, conditions and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07609654
Responsible party
Min Lou (Dr., Second Affiliated Hospital, Zhejiang University, School of Medicine) — Principal investigator
First posted
May 27, 2026
Start date
Oct 26, 2026 (estimated)
Primary completion
Nov 1, 2031 (estimated)
Completion
Feb 1, 2032 (estimated)
Last update
Oct 20, 2026

Study contacts

Min Lou, PhD, MD
Contact
lm99@zju.edu.cn
8613958007213
Wansi Zhong, MD
Contact
21718233@zju.edu.cn
8618757155806
Min Lou, PhD, MD
principal investigator · Second Affiliated Hospital, Zhejiang University, School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion